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Abstract
Background: Uterine carcinosarcoma is well known for its aggressive behavior. There is little evidence regarding
the gold standard combination chemotherapy in metastatic or locally advanced carcinosarcoma, due to poor
survival outcomes obtained with conventional scheduled chemotherapy. This case report represents the first-ever
reported objective response to a metronomic chemotherapy regimen and adds to the current literature.
Case presentation: We describe a case of a Caucasian woman diagnosed with metastatic carcinosarcoma that had
already been treated with multiple lines of conventional chemotherapy, with progressive disease. This patient had a
surprising clinical and imaging response when treated with oral metronomic cyclophosphamide.
Conclusions: We reviewed the mechanism of action implicated in metronomic chemotherapy, and correlated it
with the biology of disease in carcinosarcoma. This information may add to the current literature, providing
important insights to future clinical trials in this patient population.
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Background
Uterine carcinosarcoma accounts for less than 5 % of all
uterine malignancies [1]. This tumor type is defined as a
metaplastic malignancy similar to the biphasic compo-
nents typically presented in a metaplastic breast cancer
[2]. This tumor is well known for its aggressive behavior.
More than half of patients present with locally advanced
tumors at initial diagnosis [3, 4]. Compared with patients
with uterine carcinomas, patients diagnosed with carci-
nosarcomas tend to have worse survival outcomes when
stratified by the same matching pathologic staging [5, 6].
There is little evidence regarding the gold standard
combination chemotherapy in metastatic or locally ad-
vanced carcinosarcoma, and no definitive trials have
consistently proved superior overall survival advantages
of one combination over another. Having mentioned
that, the Gynecologic Oncology Group compared ifosfa-
mide used either alone or combined with paclitaxel as a
first-line therapy for patients with stage III or IV persist-
ent or recurrent uterine carcinosarcoma. That group
demonstrated a 31 % decrease in the risk of death (haz-
ard ratio [HR] 0.69; 95 % confidence interval [CI] 0.49–
0.97; P = 0.03) and a 29 % decrease in the risk of pro-
gression (HR 0.71; 95 % CI 0.51–0.97; P = 0.03), favoring
the combination arm. Nevertheless, toxicity was also in-
creased with combination therapy [7]. In light of this
poor prognosis, aggressive behavior, and no standard
chemotherapy regimen, new strategies based on bio-
logical alterations might potentially be associated with
better outcomes.
In this report, we describe a case of a Caucasian woman
diagnosed with metastatic carcinosarcoma that had
already been treated with multiple lines of conventional
chemotherapy, with little response. This patient had a sur-
prising clinical and imaging response when treated with
oral metronomic cyclophosphamide. The rationale be-
tween responses to metronomic chemotherapy in this par-
ticular rare malignancy is further discussed.
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Case presentation
Four years ago, a healthy 64-year-old Caucasian woman
began to experience pain in the lower abdomen, only
partially relieved by analgesics. Her past medical history
was unremarkable. Magnetic resonance imaging (MRI)
of the pelvis demonstrated a pelvic solid mass.
A total abdominal hysterectomy with bilateral
salpingo-oophorectomy was performed. The surgical
procedure also included pelvic lymphadenectomy, partial
colectomy, and cystectomy. Histopathologic staging re-
vealed a high-grade endometrial carcinosarcoma meas-
uring 14 cm in its greatest dimension. Tumor
infiltration included the uterine serosa, rectosigmoid ser-
osa, surrounding adipose tissue, cecal appendix, right
fallopian tube, and ovaries. No lymphatic or vascular in-
vasion and no involved lymph nodes were present. Peri-
toneal fluid was collected and was found to be positive
for malignant tumor cells. Her immunohistochemistry
result was positive for CD10, vimentin, AE1/3, endomy-
sial, and S100 antibodies and negative for actin, desmin,
estrogen and progesterone receptor. The patient was
given adjuvant systemic chemotherapy with six cycles of
carboplatin and paclitaxel.
The patient developed local recurrence 8 months after
the end of her chemotherapy and was referred for sur-
gery. An exploratory laparotomy revealed a high-grade
endometrial sarcoma involving the terminal ileum and
visceral peritoneum. The patient underwent a secondary
cytoreductive surgery with no residual disease. After sur-
gery, she received two cycles of ifosfamide at 2 g/m2 D1-
3 combined with epirubicin at 50 mg/m2 D1-2 every 21
days. Treatment was interrupted due to encephalopathy
and hematologic toxicity. Hematologic toxicity included
grade 4 neutropenia according to the National Cancer
Institute (NCI) Common Terminology Criteria for Ad-
verse Events (CTCAE) version 4.0. The patient devel-
oped symptoms of agitation, confusion, and seizure due
to ifosfamide-related encephalopathy. Her neurologic
symptoms were totally reversed after chemotherapy
interruption.
The patient was followed for 8 months, when fluoro-
deoxyglucose positron emission tomography–computed
tomography (FDG-PET/CT) revealed two major perihe-
patic peritoneal nodules near segment VI, along with
several other, smaller peritoneal implants. She had a
complete tertiary cytoreduction that included resection
of hepatic implants near segment VI, mesentery, and
peritoneal bladder. Her pathology results confirmed car-
cinosarcoma, with a predominant high-grade, undiffer-
entiated stromal component. Following surgery, she
received carboplatin at a target carboplatin area under
the time–concentration curve of 5, combined with doce-
taxel at 60 mg/m2; however, after the third cycle, she de-
veloped grade 3 NCI CTCAE version 4.0 infusion-
related allergy to carboplatin, and the fourth cycle in-
cluded docetaxel monotherapy at 60 mg/m2.
Five months later, MRI and FDG-PET/CT demon-
strated a peritoneal recurrence near hepatic segments
VIII and VI, as well as the precaval lymph node and hep-
atic hilum with extension to the retropancreatic space.
Nevertheless, a new attempt at cytoreductive surgery
was ruled out. She was started on topotecan at 1.25 mg/
m2 D1-5 every 21 days, but she developed progressive
disease shortly after the fourth cycle. Her clinical condi-
tion included jaundice, malaise, and a great deterioration
of PS.
Biliary stents were placed. The procedure was success-
ful, and the patient experienced considerable clinical im-
provement. The physician team decided to initiate
metronomic chemotherapy. Oral cyclophosphamide at an
empiric dose of 50 mg/day, given continuously, was
started. The patient tolerated this regimen quite well,
started to feel better, and recovered her performance sta-
tus. Abdominal MRI was performed to evaluate treatment
efficacy, and the patient was found to have a partial re-
sponse according to Response Evaluation Criteria in Solid
Tumors (RECIST) 1.1 criteria. Figure 1 displays MRI scans
obtained before and after metronomic therapy.
Three months later, the patient complained of a new
abdominal pain, and MRI demonstrated a new liver
mass that was interpreted as progressive disease. Metro-
nomic therapy was switched to a standard vinorelbine
dosing schedule, namely 25 mg/m2 D1 and D8 every 21
days. After three cycles, the patient was experiencing
worsening of her abdominal pain as well as daily fever.
Chemotherapy was discontinued. A new abdominal MRI
scan demonstrated that the liver lesion was bigger, with
a central necrotic aspect. Percutaneous drainage of the
lesion confirmed that there was a hepatic abscess. After
the procedure and antibiotic treatment, the patient’s
condition improved. This suggested that the medical
team had misinterpreted computed tomographic (CT)
scans and that the new liver lesion which had developed
while the patient was on metronomic chemotherapy was
a liver abscess. Earlier this year, cyclophosphamide was
reinitiated, and a new MRI performed 3 months after
treatment initiation revealed a partial response based on
RECIST 1.1. The patient has continued with oral cyclo-
phosphamide therapy through the time of this report.
Tomographic evaluation was performed in December
2015, and the images demonstrated a partial response in
comparison to the initial CT scans performed before
cyclophosphamide treatment. The patient’s progression-
free survival is 22 months at the time of this report.
Discussion
In this case report, we described a heavily pretreated pa-
tient diagnosed with carcinosarcoma who experienced
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an objective response to metronomic therapy. The bio-
logic rationale involved in this response might be related
to a high dependence on vascular growth factors for dis-
ease progression. It is import to emphasize that optimal
dosing and scheduling of metronomic chemotherapy re-
mains a challenging subject, with no data derived from
randomized controlled trials to guide precise, optimal
scheduling. We chose to provide our patient the empiric
dosing of 50 mg/day of cyclophosphamide continuously.
The more aggressive clinicopathologic characteristics
observed in uterine carcinosarcomas might be supported
by the high degree of angiogenic activity in these tu-
mors. Vascular endothelial growth factor (VEGF), pro-
duced by cancer cells, is considered to be a critical
activator of vascular endothelial cells, and its expression
has been associated with increased angiogenesis in many
human tumors, including gynecologic malignancies [2,
8, 9]. Of note, the largest analysis of VEGF protein ex-
pression in uterine carcinosarcoma was performed by
Emoto et al., who demonstrated by in situ hybridization
high levels of VEGF expression in 35 primary uterine
carcinosarcomas [8]. Other researchers also have dem-
onstrated high levels of immunohistochemical staining
of VEGF in these tumors, especially at the mesenchymal
component. Additionally, VEGF staining has been asso-
ciated with poor survival outcomes [2, 9, 10].
Uterine carcinosarcoma also was found to display a
specific microRNA (miRNA or miR) signature in at least
two different studies. Compared with benign endomet-
rium or with epithelial uterine tumors (endometrioid or
papillary serous), uterine carcinosarcomas are a biologic-
ally distinct disease, further supporting the hypothesis
that these tumors require a therapeutic strategy distinct
from those used for other epithelial tumors [11, 12].
Certain miRNAs appear to be consistently altered in the
carcinosarcomas. In fact, miR-20b, a known regulator of
VEGF, is upregulated in carcinosarcoma cells. miR-20b
has been described as playing an important oncogenic
role in solid malignancies, and its high expression is as-
sociated with tumor cell growth. Comparatively, low ex-
pression of miR-20b inhibits tumor cell growth and is
associated with resistance to apoptosis in hypoxic condi-
tions by upregulation of tumor cell VEGF [13, 14]. Thus,
a possible reason to maintain tumor adaptation to hyp-
oxia is through low expression of VEGF, as tumor stro-
mal cells may act as a source of VEGF [14].
The concept of metronomic chemotherapy is based on
a treatment that is delivered more frequently and with
low daily doses. Cyclophosphamide is the most widely
explored agent in such an approach. Its mechanism of
action is regarded as primarily antiangiogenic in nature,
affecting both the endothelial cells of tumor-supplying
blood vessels and the circulating endothelial progenitor
cells. In addition, recent evidence points to the presence
of immunomodulatory antitumor activities in metro-
nomic therapy. However, the importance of such im-
munologic and other direct anticancer cells effects, such
as the interference with the hypoxia-induced factor 1α
pathway, along with targeting cancer stem cells, remains
undetermined [15–18]. Retrospective studies and nu-
merous phase II clinical trials have been published in di-
verse clinical scenarios, mainly in patients with highly
pretreated advanced tumors. Also, metronomic chemo-
therapy was an attractive strategy in our patient, whereas
it was associated with a very favorable toxicity profile
and less financial cost [15, 18].
Fig. 1 T2- and diffusion-weighted magnetic resonance imaging scans (b = 600). In the top row, blue arrows indicate hepatic lesions and
red arrows indicate abdominal lymphadenopathy at baseline. In the bottom row, scans taken after metronomic chemotherapy treatment show
a major reduction at the hepatic lesions (green arrows) as well as at the abdominal lymphadenopathy
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Antiangiogenic therapies in uterine carcinosarcoma
were previously evaluated in vitro and in vivo in preclin-
ical studies, with promising results [19, 20]. In the clin-
ical setting, different antiangiogenic drugs were tested in
metastatic disease. Aflibercept, pazopanib, and thalido-
mide demonstrated activity, which suggests the concept
that angiogenesis is an important pathway in carcinosar-
coma development [21–23]. Several other targeted strat-
egies have now been developed [2, 24].
Conclusions
Uterine carcinosarcoma is a rare and aggressive disease,
with no standard treatment, especially in a recurrent or
progressive disease setting. In this case report, we review
the mechanism of action implicated in metronomic
chemotherapy, exploring an antiangiogenic strategy in a
patient diagnosed with advanced carcinosarcoma. More
details are necessary to establish a standard treatment,
but this report adds to the current literature.
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